Benzinga | Aug 4, 2020 10:16AM EDT

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $145

Canaccord Genuity maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $134 to $145.